Table 1 Summary of patients who underwent surgery for solid tumors with sarcoid reactions reported between 2012 and 2022, including the present cases
Patient | Author | Year | Age | Sex | Primary tumor | TNM stage | Adjuvant therapy for primary cancer | Tumor recurrence | Location of sarcoid reaction | Solitary or multiple | Time of sarcoid reaction after surgery |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Tao [5] | 2012 | 59 | F | Lung cancer | N/A | None | No (1Â year) | Lung parenchyma and lymph nodes | Multiple | Simultaneous |
2 | Fong [21] | 2012 | 59 | M | Cholangiocarcinoma | N/A | None | No (9Â months) | Spleen | Multiple | Simultaneous |
3 | Fong [21] | 2012 | 68 | F | IPMN with carcinoma in situ | N/A | None | No (9Â months) | Spleen, liver, bone | Multiple | Simultaneous |
4 | Quellet [30] | 2012 | 62 | M | Renal cancer | N/A | None | No (30Â months) | Normal renal parenchyma | Multiple | Simultaneous |
5 | Craun [31] | 2012 | 34 | F | Bone cancer | N/A | Radiation therapy | Yes (less than 1Â year) | Mediastinal, hilar, right axillary, and right neck lymph nodes | Multiple | 4Â years |
6 | Mastroroberto [22] | 2012 | 52 | M | Neuroendocrine tumor of the pancreas | N/A | None | N/A | Lymph nodes | Multiple | Simultaneous |
7 | Burhan [29] | 2013 | 62 | M | Renal cancer | N/A | None | N/A | Nephrectomy specimen | Solitary | Simultaneous |
8 | Fiorelli [19] | 2014 | 67 | F | Colorectal cancer | N/A | 6 cycles of adjuvant | No | Paratracheal lymph node | Multiple | 5Â years |
9 | Kawasaki [20] | 2014 | 73 | F | Gallbladder cancer | T1bN0M0, stage IA | None | No (4Â years) | Regional lymph node | Multiple | Simultaneous |
10 | Ritterhouse [27] | 2014 | 34 | F | Renal cancer | T1b | None | No (22Â months) | Tumor stroma | Multiple | Simultaneous |
11 | Madden [28] | 2014 | 41 | M | Renal cancer | T3aNxMx | None | No (15Â months) | Axial and proximal appendicular skeleton | Multiple | 2Â years |
12 | Khatua [26] | 2015 | 42 | F | Renal cancer | N/A | None | N/A | Intratumoral epithelioid granuloma | Multiple | Simultaneous |
13 | Rubinstein [11] | 2015 | 76 | F | Breast cancer | N/A | Radiation and tamoxifen | No (30Â months) | Right preauricular and right upper cervical sentinel lymph nodes | Multiple | N/A |
14 | Shima [17] | 2016 | 76 | F | Colorectal cancer | T3N2M0 | S-1, FOLFOX | Yes (4Â months) | Spleen | Solitary | 20Â months |
15 | Diaz del Arco [18] | 2016 | 55 | M | Colorectal cancer | T3N1M0 | None | N/A | Within the stroma adjacent to the carcinoma | Multiple | Simultaneous |
16 | Pascual-Camps [6] | 2017 | 60 | M | Lung cancer | T2bN0M0, stage IIA | None | Yes | Lymph nodes and tumor, ocular | Multiple | Simultaneous |
17 | De Gregorio [16] | 2018 | 32 | F | Colorectal cancer | T3N1M0 | FOLFOX + cetuximab | No | Bilateral mediastinal and hilar lymph nodes | Multiple | Simultaneous |
18 | Iftikhar [25] | 2019 | 45 | F | Renal cancer | N/A | None | N/A | Mediastinal and bilateral hilar nodes | Multiple | 1Â year |
19 | Garanzini [24] | 2019 | 66 | F | Melanoma | T3N1aM0 | Ipilimumab | No (5Â years) | Lung and spleen | Multiple | 20Â months |
20 | Yousuf [7] | 2020 | 62 | F | Lung cancer | T1cN0M0 | Pembrolizumab | N/A | Mediastinal and right hilar and subcarinal lymphadenopathy | Multiple | N/A |
21 | Irie [13] | 2020 | 52 | F | Esophageal cancer | T1N0M0, stage IA | 5-Fluorouracil, docetaxel plus cisplatin | No (4Â years) | Regional lymph node | Multiple | Simultaneous |
22 | Okada [14] | 2020 | 82 | M | Gastric cancer | T3N0M0, stage IIA | None | No (24Â months) | Spleen | Solitary | 6Â months |
23 | Aedma [15] | 2020 | 54 | M | Colorectal cancer | IVB | FOLFOX + bevacizumab | No (18 months) | Hepatosplenic lesions, mediastinal and bilateral hilar lymph nodes | Multiple | 6 months |
24 | Frohlich [23] | 2020 | 57 | M | Melanoma | T4N1M0, stage IIIc | Either ipilimumab or nivolumab | No (40Â weeks) | Bilateral hilar, prevascular, and right lower paratracheal lymphadenopathy | Multiple | 14Â weeks |
25 | Shi [8] | 2021 | 68 | F | Lung cancer | T4N0M0, stage IIIA | Pembrolizumab | No | Lung and mediastinal lymph node | Multiple | Simultaneous |
26 | Jeong [10] | 2021 | 58 | F | Breast cancer | T1aN0M0 | Cytoxan, methotrexate, and fluorouracil | N/A | Bilateral supraclavicular, bilateral mediastinal, and intraperitoneal areas | Multiple | 40Â months |
27 | Zhao [9] | 2022 | 54 | F | Lung cancer | T2N0M0, stage IB | Nivolumab | N/A | Lymph nodes | Multiple | Simultaneous |
28 | Present case 1 | Â | 67 | F | Uterine cancer | T1aN0M0, stage IA | None | No (4Â years) | Spleen | Multiple | 3Â years |
28 | Present case 2 | Â | 47 | F | Uterine cancer | T1aN0M0, stage IA | None | No (5Â years) | Spleen and lymph node | Multiple | 2Â years |